3 Undervalued Health Care Stocks to Watch in September

Boston Scientific Corp (BSX), aTyr Pharma Inc (ATYR), and Reviva Pharmaceuticals Holdings Inc (RVPH) are oversold stocks in the healthcare sector with RSI values of 27.3, 22.6, and 24.5, respectively. Oppenheimer analyst Steven Lichtman upgraded Boston Scientific from Perform to Outperform, raising the price target to $125. aTyr Pharma announced Phase 3 EFZO-FIT study results that did not meet the primary endpoint, while Reviva Pharmaceuticals Holdings priced a $9 million public offering.

Oppenheimer analyst Steven Lichtman recently upgraded Boston Scientific Corp. (BSX) from Perform to Outperform, raising the price target to $125. This move comes as shares of BSX entered oversold territory, with an RSI reading of 27.3. This indicates a potential buying opportunity as the recent heavy selling may be exhausting itself Relative Strength Alert For Boston Scientific^[1].

Meanwhile, aTyr Pharma Inc. (ATYR) faces investor scrutiny following the failure of its Phase 3 EFZO-FIT study, which did not meet its primary endpoint. The company's shares cratered over 80% after the announcement, with an RSI reading of 22.6. Investors are urged to submit their losses and provide information to Hagens Berman, a national shareholders rights firm investigating potential investor misconduct aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman^[2].

Reviva Pharmaceuticals Holdings Inc. (RVPH) also finds itself in oversold territory with an RSI reading of 24.5. The company priced a $9 million public offering, including 27 million shares of common stock and warrants, priced at $0.335 per share. This offering signals significant dilution for existing shareholders but provides crucial funding for the company's research and development pipeline Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering^[3].

These developments highlight the potential risks and opportunities in the healthcare sector. Investors should closely monitor these companies and consider their individual investment strategies.